Nov. 14, 2022 -- Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023. Appointed Greg Mayes as President and Chief Executive Officer, with Joseph del Moral moving into the role of Chairman...
TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its ...
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that the Company will ...
Company Continues to Deepen Executive Bench with Life Science Industry Veterans TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for ...
“Raising Capital for Psychedelic Endeavors” Panel Part of Conference’s Psychedelic Business Forum TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel serotonergic psychedelic drug development committed to ...
TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc . (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor ...
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will ...
TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the “ Meeting ”)...
Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug ...
TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate ...